

## HR 7640

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** May 3, 2022

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (May 3, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/7640>

### Sponsor

**Name:** Rep. Bilirakis, Gus M. [R-FL-12]

**Party:** Republican • **State:** FL • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Butterfield, G. K. [D-NC-1]	D · NC		May 3, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	May 3, 2022

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
117 S 4348	Related bill	<b>Jul 13, 2022:</b> Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.

### Summary (as of May 3, 2022)

This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.

### Actions Timeline

- **May 3, 2022:** Introduced in House
- **May 3, 2022:** Referred to the House Committee on Energy and Commerce.